FDA approves perampanel as adjunctive treatment for partial-onset seizures in patients with epilepsy aged 12 years and older

Article

FDA has approved perampanel (Fycompa, Eisai), an AMPA receptor antagonist, as an adjunctive treatment of partial-onset seizures with or without secondarily generalized seizures in patients aged 12 years and older who have epilepsy.

Newsletter

Pharmacy practice is always changing. Stay ahead of the curve with the Drug Topics newsletter and get the latest drug information, industry trends, and patient care tips.

Recent Videos
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series.
2 experts are featured in this series
Image Credit: jokekung - stock.adobe.com
Related Content
© 2025 MJH Life Sciences

All rights reserved.